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Running title: Cost-effectiveness of a model consultation for osteoarthritis 
 
ABSTRACT 
Objectives: The aim of this study was to estimate the cost-effectiveness of a model OA 
consultation for osteoarthritis to support self-management compared with usual care.   
Methods: An incremental cost-utility analysis using patient responses to the 3-level EQ-5D 
questionnaire was undertaken from a UK National Health Service perspective alongside a 
two-arm cluster-randomised controlled trial. Uncertainty was explored through the use of 
cost-effectiveness acceptability curves.  
Results: Differences in health outcomes between the model OA consultation and usual care 
arms were not statistically significant. On average, visits to the orthopaedic surgeon were 
lower in the model OA consultation arm -0.28 (95% CI: -0.55, -0.06). The cost-utility 
analysis indicated that the model OA consultation was associated with a non-significant 
incremental cost of £-13.11 (95% CI: -81.09, 54.85) and an incremental QALY of -0.003 
(95% CI: -0.03, 0.02), with a 44% chance of being cost-effective at a threshold of £20,000 
per QALY gained. The percentage of participants who took time off and the associated 
productivity cost was lower in the model OA consultation arm. 
Conclusion: Implementing NICE guidelines using a model OA consultation in primary care 
does not appear to lead to increased costs, but health outcomes remain very similar to usual 
care. Even though the intervention seems to reduce the demand for orthopaedic surgery, 
overall it is unlikely to be cost-effective.  
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Key messages 
• A model OA consultation offers a practical approach that supports self-management 
of OA. 
• Implementing NICE guidelines using a model OA consultation in primary care does 
not appear to lead to increased costs. 
• The model OA consultation appears to reduce referrals to orthopaedic surgery, and 
may result in less time off work. 
• The model OA consultation is unlikely to be cost-effective 
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INTRODUCTION 
Osteoarthritis (OA) is most prevalent in older people and is known to adversely affect quality 
of life [1-3].  Estimates from the USA suggest that 12.4 million adults over the age of 65 are 
living with this condition and around 2.9 million people have a disabling form of OA. A 
report by the Royal College of General Practitioners indicates that about 1 million adults 
consult with symptoms of OA in a year and it is one of the main reasons why people seek 
medical care [4-6]. The total healthcare cost of OA has been estimated at £1 billion in the UK 
[5]. Therefore OA places a considerable burden on scarce health care resources. The 
proportion of older people in the population has been increasing over time [7], and with this 
ageing population, it is expected that the prevalence of conditions such as OA will rise. A 
number of published guidelines have been developed to aid the treatment and management of 
OA [8-12]. In the UK for example, the National Institute for Health and Care Excellence 
(NICE) recommend that patients with OA should be offered core treatments when they first 
present in primary care. These include education and access to information, advice on local 
muscle strengthening exercise and general aerobic fitness, and if appropriate, advice on 
losing weight [12]. However, there is a gap between the care that is recommended and that 
which patients actually receive and that the core aspects of assessment and management of 
OA currently delivered in primary care do not meet the recommendations of these guidelines 
[13-14]. Therefore measures need to be put in place to ensure that resources are used 
optimally. Consequently, there was a need to develop a practical approach that could 
potentially support self-management of OA and also aid the implementation of the core NICE 
guidelines for OA. This led to the development of a model OA consultation [15] for older 
patients presenting with peripheral joint pain, and training for health care professionals to 
support its delivery. The model OA consultation integrated core recommendations from 
NICE and consisted of: an OA guidebook written by patients and health professionals for 
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patients, an enhanced initial consultation with a GP, and subsequent follow-up with a practice 
nurse (up to 4 consultations) in a dedicated nurse-led OA clinic. In addition a practice e-
template was developed to record quality measures of care derived from a systematic review 
of quality indicators for OA [15-16]. The Management of OsteoArthritis in Consultations 
(MOSAICS) trial compared the model OA consultation with usual care over a 12 month 
period. This paper reports the economic evaluation alongside the MOSAICS trial to assess 
the cost-effectiveness of the model OA consultation compared with usual care in patients 
who consult with OA. 
METHODS 
The economic evaluation was conducted alongside a two arm prospective pragmatic cluster 
randomised controlled trial in eight general practices in Cheshire, Shropshire or Staffordshire, 
UK. The protocol has been previously published [15]. The eight practices were randomised to 
receive either the model OA consultation or usual care (control). Additional details of the 
intervention can be found in appendix 1. The study was approved by the North West 1 
Research Ethics Committee, Cheshire (REC reference: 10/H1017/76) and was monitored by 
an Independent Trial Steering Committee and Data Monitoring Committee (Trial registration 
number ISRCTN06984617). The primary outcome measure for the trial was the SF-12 
physical component score [17].      
The health economic analysis initially took the form of a cost-consequence analysis where a 
description of all the important results relating to costs and consequences (clinical outcomes, 
EQ-5D, SF-6D, ICECAP-A) were reported. Subsequently, an incremental cost-utility 
analysis using the quality adjusted life year as an outcome measure was undertaken from a 
UK National Health Service (NHS) perspective.   
Data Collection 
Page 6 of 25Rheumatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Resource Use and Costs 
Information on resource use and time off work due to joint problems were collected from the 
postal MOSAICS consultation questionnaires completed by participants at 6 months and 12 
months follow-up. NHS costs included primary and secondary care contacts, investigations, 
medication and contacts with other health care professionals such as physiotherapists and 
occupational therapists. Questions on participant’s personal expenditure focused on private 
health care use and over-the-counter treatments [15].   
In order to value resource use, unit costs were obtained from standard sources such as the 
Unit Costs of Health and Social Care [18], the British National Formulary [19] and NHS 
Reference Costs [20] and applied to resource use data. Due to the lack of nationally 
representative unit cost estimates for private health care, this care was costed as the NHS 
equivalent. To obtain the cost of the model OA consultation, information on the resources 
used to deliver the intervention were obtained from patient records collected throughout the 
trial. To generate the intervention cost, we obtained records collected as part of the 
intervention. These records showed that the average number of times that trial participants 
actually saw their nurse from available records was 2.3 times. We therefore made the 
assumption that everyone in the intervention arm who actually saw the nurse did so at least 
2.3 times. GP costs were not included as part of the intervention since all participants, 
irrespective of trial intervention arm received usual care. Costs associated with over the 
counter medication were based on participant responses to the postal questionnaires. Unit 
costs of the resource use items are presented in appendix 2 and are in 2012/2013 prices.  
Health and Quality of Life Outcomes 
All participants completed the 3-level version of the EuroQoL-5D (EQ-5D) questionnaire 
[21] at baseline, 3, 6 and 12 months. EQ-5D index scores were generated using the UK value 
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set [22] to calculate quality adjusted life years (QALYs) over the 12 month period which was 
used in the base case analysis. (The QALY is an outcome measure that takes both the quality 
and quantity of life associated with an intervention into account). Participants also completed 
the SF-12 questionnaire [17] which was used to generate SF-6D scores [23] and the ICECAP-
A questionnaire at baseline, 3, 6 and 12 months. The ICECAP-A is a measure of capability 
for adults, which aims to capture an individual’s freedom to function in five key areas of their 
life: attachment, autonomy, enjoyment, stability and achievement [24].  
Statistical Analysis  
Descriptive statistics were used to summarise the main health economic outcomes (EQ-5D 
3L, SF-6D and ICECAP-A). The cost-utility analysis was focused on determining the 
difference in costs and QALYs between the model OA consultation and usual care arms. To 
ensure all eligible participants were included in the study, missing EQ-5D, SF-6D, ICECAP-
A and costs were imputed using multiple imputation methodology [25]. An imputation model 
was fitted and included 25 imputed dataset. Using EQ-5D scores, QALYs over a 12 month 
time period were calculated for each study participant with the area under the curve method 
[26]. Imbalances in baseline utility (EQ-5D) scores between the model OA consultation and 
usual care arms were controlled for using a multiple linear regression approach [27]. Mean 
costs associated with each trial arm were estimated, and due to the skewed nature of the costs, 
the difference in mean costs and 95% confidence intervals were calculated using non-
parametric bootstrapping [28]. Net monetary benefit (∆E*λ –∆C) was also estimated for each 
participant. This is defined as the change in effectiveness/QALYs (∆E) multiplied by the 
cost-effectiveness threshold (λ) minus the change in cost (∆C) [29].  The threshold value (λ) 
used for the estimation of net benefits was £20,000 per QALY. 
The base case took the form of a cost-utility analysis from a National Health Service (NHS) 
perspective and was conducted using multilevel linear modelling (as participants are 
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clustered within GP practices), a method that has been recommended for the economic 
evaluation of cluster trials [30]. The dependent variables were net monetary benefits, costs, 
QALYs and cost of work absence. Independent variables included gender and baseline EQ-
5D. Model estimates of the difference in costs, QALYs and net monetary benefits were used 
to derive an incremental cost per QALY gained and an incremental net monetary benefit.  
Uncertainty was explored through the use of cost-effectiveness planes and cost-effectiveness 
acceptability curves (CEACs); these plot the probability that the intervention is cost-effective 
against willingness to pay threshold values [31]. All analyses were carried out in STATA 12, 
Realcom and Microsoft Excel [32-34]. Discounting was not required as the follow up period 
was 12 months. 
Sensitivity Analysis 
The sensitivity analysis had two main foci. The first was to explore uncertainties in the trial 
based data by using QALYs generated from the SF-6D to obtain cost-effectiveness estimates. 
The second was to explore broader societal costs through the inclusion of private health care 
costs e.g. over the counter medication costs and private health care utilisation costs as well as 
productivity costs. The human capital approach [35], was used to estimate productivity costs 
using data collected on employment status at every time point and days off work due to their 
health. The average wage for each respondent was identified using UK Standard 
Occupational Classification coding and annual earnings data for each job type [36].  
RESULTS 
A total of 525 participants across the 8 randomised practices were recruited to the cluster 
trial. Of these, 288 participants were in the practices randomised to the model OA 
consultation arm and 237 in practices randomised to the usual care arm.  The mean age across 
all patients was 67.3 years (SD 10.4) and 59.5% were female. Follow-up rates at 6 and 12 
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months were 424 (81%) and 384 (73%) respectively in the intervention and control arms. A 
total of 305 (58.1%) participants provided complete EQ-5D data at all time points.  
Resource use  
Primary care visits were generally higher in the usual care arm. Although the differences 
were not statistically significant, participants in the usual care arm had more visits to both the 
GP and nurse. There was no significant difference in secondary care visits between trial arms 
with the exception of visits to the orthopaedic surgeon which was significantly higher in the 
usual care arm. Approximately 65% of participants in the usual care arm had prescribed 
medication as compared to 59% in the model OA consultation arm (Table 1).  
Health Outcomes 
Mean EQ-5D and SF-6D scores increased at all time points over the 12 month period in both 
the intervention and usual care arms indicating an improvement in health status over time. 
Although these scores were higher in the usual care arm, the differences were not statistically 
significant. When total QALYs were estimated, the usual care arm was associated with 
marginally higher overall QALYs (in respect to both the EQ-5D and SF-6D). Also, the results 
for the between-group differences in ICECAP-A showed similarly that the usual care arm 
showed slightly higher average levels of capability across follow-up  (Table 2). EQ-5D scores 
were generally lower than SF-6D scores at all times.  
Costs 
Overall NHS and health care costs were also higher in the usual care group compared with 
the model OA consultation arm. However, these differences were not statistically significant 
(Table 3).  Table 3 also gives a breakdown of costs for each intervention. Use of primary and 
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secondary care, including visits to the orthopaedic surgeon, was greater in the usual care arm 
leading to higher costs.  
Cost-effectiveness 
Estimates from the regression model show that the intervention was associated with a lower 
cost (p=0.705) and fewer QALYs (p=0.786) (Table 4). At a willingness to pay threshold of 
£20,000 per QALY, the model OA consultation was associated with a 44% chance of being 
cost-effective (Figure 1).  
Sensitivity Analysis 
When broader health care costs were used, the intervention was still less costly (p=0.768) and 
less effective (p=0.786) than the usual care arm (Table 5). Cost-utility analysis with QALYs 
generated from the SF-6D yielded similar results to the base case analysis i.e. the intervention 
was less costly (p=0.705) and less effective (p=0.187) than the usual care (Table 5). A total of 
136 participants were in full time employment at baseline. Of these, 40 participants, 20 in 
each trial arm took time-off over the 12 month period. Those in the intervention arm had 
fewer mean days off work than those in the usual care arm (p=0.364).  The associated 
productivity related cost was lower in the intervention arm but the difference was not 
statistically significant (Table 5).  
DISCUSSION 
Summary of main findings 
This study sought to assess the cost-effectiveness of the model osteoarthritis consultation 
(model OA consultation) for the implementation of NICE guidelines and support for self-
management of osteoarthritis in primary care. Our results reveal that there was a general 
increase in health status across the whole population as measured by the EQ-5D and SF-6D 
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over the 12 month period, and although scores were slightly higher in the usual care arm, the 
difference was not statistically significant. SF-6D scores were higher than EQ-5D scores, a 
result which was in line with a previous study [37]. With the exception of visits to the 
orthopaedic surgeon, which was higher in the usual care group, there were no significant 
differences in all other secondary care resource use items between the trial arms. Participants 
in the usual care arm also reported more time-off work compared to the intervention arm. The 
finding that the intervention may lead to reduced referrals and less time off work suggests a 
possible avenue for future research to identify individual patients who might benefit from the 
approach.  
The model OA consultation was less expensive than usual care and although this was not 
statistically significant, one might argue that the exclusion of the cost of training resulted in 
this lower cost. However, it should be noted that there are difficulties associated with the 
estimation of a per patient training cost within economic evaluation studies and also training 
received would be used for a large number of patients over a number of years, resulting in a 
low mean cost per patient.   
The cost-utility analysis showed that the model OA consultation was less costly but less 
effective than usual care. Even though these differences are not statistically significant, the 
established approach that is used in health economics is to conduct a cost-effectiveness 
analysis, focussing on the joint estimation of costs and outcomes [38]. At a cost-effectiveness 
threshold of £20,000 per QALY, the probability of the model OA consultation being cost-
effective was low at 44%.  
Strengths and weakness of the study 
A major strength of this study is that it is the first to consider the cost-effectiveness of the 
model OA consultation for the implementation of NICE guidelines and support for self-
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management of OA in primary care. Second, the study considered cost-effectiveness in a 
population consulting with peripheral joint pain and OA in primary care. Much of the cost-
effectiveness studies for OA are based on studies of knee OA and as such, our study 
considered a population where evidence of cost-effectiveness is lacking. Third, this study 
considered multiple outcomes and also considers outcomes broader than just health related 
quality of life which makes it unique from other health economic evaluations which consider 
a single outcome measure. This study is also associated with some limitations. First  is the 
fact that the main outcome for the health economic analysis was the 3-level EQ-5D which 
may not be sensitive to changes in this disease area [39]. The five level version of the EQ-5D 
[40] is now available and this is likely to be more sensitive to change. Second, the difficulty 
associated with the estimation of a per patient training cost led to the exclusion of this cost 
from the analysis. 
Meaning of the study 
Implementing NICE guidelines using a model OA consultation in primary care may not lead 
to increased costs. Although the intervention may support some people with OA to remain in 
work and reduce the demand for orthopaedic surgery, overall it is unlikely to be cost-
effective.  
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TABLE 1: Resource Use over 12 months Complete cases. All figures are means 
(standard deviations) except where indicated 
Resource use category Model OA 
consultation 
(n=199) 
Usual care 
(n=155)  
Difference 
(Bootstrapped 95% 
Confidence Interval) 
Primary Care visits 
a
 1.52 (2.46) 1.99 (3.38) -0.48 (-1.18, 0.13) 
GP at practice 1.32 (2.11) 1.59 (2.62) -0.28 (-0.78, 0.24) 
GP at home 0.02 (0.12) 0.01 (0.08) 0.01 (-0.11, 0.03) 
Nurse at practice 0.19 (0.67) 0.39 (1.29) -0.20 (-0.48, -0.01) 
Nurse at home 0 0.01 (0.08) -0.01 (-0.03, 0) 
Other healthcare 
professionals 
(attached to 
practice) 
d
 
0.21 (0.86) 0.32 (1.15) -0.12 (-0.33, 0.11) 
Secondary care visits 
b
 1.11 (2.65) 1.43 (2.91) -0.32 (-0.96, 0.27) 
Orthopaedic 
surgeon 
0.34 (0.89) 0.58 (1.37) -0.24 (-0.52, -0.003) 
Podiatrist 0.13 (0.92) 0.12 (0.80) 0.003 (-0.17, 0.17) 
Physiotherapist 0.61 (2.01) 0.65 (1.93) -0.04 (-0.47, 0.36) 
Occupational 
therapist 
0.04 (0.21) 0.07 (0.58) -0.04 (-0.16, 0.04) 
Other secondary 
care visits 
d
 
0.16 (0.91) 0.10 (0.51) 0.06 (-0.07, 0.24) 
Private 
consultants 
c
 
0.39 (1.66) 0.57 (3.07) -0.18 (-0.79, 0.29) 
Private other 
health care 
professionals 
d
 
0.13 (0.85) 0.04 (0.28) 0.09 (-0.02, 0.23) 
 
Hospital 
investigations/treatments 
d,e
 
82 (41.21%) 72 (46.45%) 10 
Prescribed drugs 
d,e
 117 (58.79%) 101 
(65.16%) 
16 
Over the counter drugs 
d,e
 
98 (49.25%) 72 (46.45%) 26 
a
 Includes contacts with GP and Nurse at home and practice 
b
 Includes contacts with physiotherapists, 
occupational therapists podiatrists, and orthopaedic surgeons 
c
 Includes contacts with private physiotherapists, 
occupational therapists private podiatrists and private orthopaedic surgeons d Patient-specific e Figures are the 
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number of patients (percent) who stated that they had a investigation or a drug           * Resource use items 
presented in this table were solely obtained from self report questionnaires 
 
TABLE 2: Health Outcomes Mean (SD) over 12 months (imputed analysis) 
 Model OA 
consultation 
(n=288) 
Usual care 
(n=237) 
Difference 
(Bootstrapped 95% 
 Confidence Interval) 
EQ-5D scores    
Baseline 0.573 (0.298) 0.588 (0.272) -0.015 (-0.062 , 0.039) 
Month 3 0.615 (0.280) 0.631 (0.264) -0.016 (-0.064 , 0.030) 
Month  6 0.637 (0.264) 0.638 (0.259) -0.001 (-0.044 , 0.044) 
Month 12 0.651 (0.262) 0.674 (0.224) -0.023 (-0.067 , 0.018) 
QALYs  0.627 (0.244) 0.639 (0.224) -0.012 (-0.054 , 0.026) 
QALYs
a
 0.632 0.634 -0.002 (-0.25, 0.020) 
QALYs
b
 -0.003 (-0.026 , 0.197) 
SF 6D scores    
Baseline 0.678 (0.139) 0.690 (0.148) -0.012 (-0.037 , 0.013) 
Month 3 0.688 (0.141) 0.696 (0.141) -0.008 (-0.033 , 0.017) 
Month 6 0.687 (0.142) 0.707 (0.144) -0.020 (-0.044 , 0.004) 
Month 12 0.693 (0.139) 0.702 (0.138) -0.009 (-0.032 , 0.015) 
QALY  0.688 (0.128) 0.701 (0.129) -0.013 (-0.038 , 0.010) 
QALY
a
 0.692 0.696 -0.004 (-0.03, 0.01) 
QALYs
b
 -0.012 (-0.03 , 0.01) 
ICECAP A    
Baseline 0.826 (0.166) 0.851 (0.155) -0.025 (-0.053 , 0.003) 
Month 3 0.828 (0.151) 0.853 (0.155) -0.025 (-0.053 , 0.001) 
Month  6 0.821 (0.160) 0.843 (0.158) -0.022 (-0.049 , 0.005) 
Month 12 0.837 (0.153) 0.846 (0.155) -0.009 (-0.038 , 0.014) 
a
 adjusted for baseline Utility    
b 
difference in
 
QALYs between trial arms adjusted for baseline Utility and 
gender (Regression model)                   
                      
TABLE 3:  Mean per patient costs (SD) over 12 months (£)    
Resource use category  Model OA 
consultation  
Usual care  Difference 
(Bootstrapped 95% 
Confidence Interval) 
 n=199 (£) n=155 (£)  
Primary Care visits 
a
 56.01 (83.53) 69.02 (103.31) -13.01 (-35.24, 5.28) 
GP at practice 44.76 (71.80) 54.18 (89.01) -9.42 (-29.03, 7.41) 
GP at home 0.81 (6.55) 0.35 (4.31) 0.46 (-0.71, 1.55) 
Nurse at practice 2.11 (7.46) 4.61 (15.07) -2.49 (-5.50, -0.03) 
Nurse at home 0 0.15 (1.87) (-0.54, 0) 
Other primary 
care visits 
c
 
8.33 (24.20) 9.74 (29.72) -1.41 (-7.37, 3.97) 
Secondary care visits 
b
 60.68 76.48 (156.38) -15.80 (-51.40, 14.01) 
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(130.42) 
Orthopaedic 
surgeon 
27.09 (71.66) 44.31 (106.94) -17.22 (-37.95, 1.18) 
Podiatrist 5.32 (35.65) 4.34 (26.23) 0.98 (-5.03, 7.93) 
Physiotherapist 21.55 (77.01) 21.74 (70.72) -0.18 (-15.47, 16.50) 
Occupational 
therapist 
2.06 (11.98) 2.24 (16.93) -0.18 (-3.50, 2.61) 
Other secondary 
care visits 
c
 
4.67 (17.85) 3.85 (22.67) 0.81 (-4.45, 4.65) 
Hospital 
investigations/treatments 
c
 
109.71 
(401.16) 
92.36 (222.66) 17.35 (-42.40, 83.75) 
Prescribed drugs 
c
 15.51 (20.34) 15.65 (21.47) -0.14 (-4.58, 3.86) 
Trial intervention cost  11.47 (20.69) 0 11.47 (8.69, 14.42) 
Over the counter drugs 
c
 27.14 
(255.67) 
27.93 (121.01) -0.79 (-31.51, 50.14) 
Private health 
professionals 
c
 
21.62 (76.54) 29.53 (135.05) -7.91 (-39.24, 12.24) 
Imputed analysis 
 Model OA 
consultation 
(n=288) 
Usual care 
(n=237) 
Difference 
(Bootstrapped 95% 
 Confidence Interval) 
Total NHS costs 
d
 227.17 
(411.84) 
236.11 (345.35) -8.94 (-71.79, 57.70) 
Total Healthcare costs 
d
 278.56 
(535.43) 
285.99 (400.43) -7.43 (-76.41, 76.26) 
a Includes contacts with GP and Nurse at home and practice  
b 
Includes contacts with physiotherapists, 
occupational therapists etc 
c
 Patient-specific  
d 
Unadjusted costs 
TABLE 4: Base case Cost-utility analysis (Imputed analysis) 
 Difference in 
mean 
(Intervention-
control)
b
 
P-value Confidence 
Interval 
Interpretation 
NHS costs (£) 
a
 -13.11 0.705 -81.09, 54.85 Intervention less 
costly and less 
effective.   
QALYs 
a
 -0.003 0.786 -0.03 , 0.02 
Net monetary 
benefits (£) 
a
 
-33.63 0.887 -497.56, 430.30 
 
a 
adjusted for baseline Utility and gender 
b 
Difference in mean per patient cost and QALYs 
between trial arms 
TABLE 5: Sensitivity analysis  
 Difference in 
mean 
(Intervention-
control)
b
 
P-value Confidence 
Interval 
Interpretation 
Cost-utility analysis with SF-6D 
NHS costs (£) 
a
 -13.11 0.705 -81.09, 54.85 Intervention less 
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QALYs (SF-
6D)
a
 
-0.012 0.187 -0.03 , 0.01 costly and less 
effective.  
Net monetary 
benefits (£) 
a
 
-178.39 0.362 -561.74 , 204.96 
Cost-utility analysis with Health care costs 
Health care 
costs (£) 
a
 
-14.14 0.768 -108.08, 79.80 Intervention less 
costly and less 
effective  QALYs 
a
 -0.003 0.786 -0.03 , 0.02 
Net monetary 
benefits (£) 
a
 
-34.95 0.883 -501.82 , 431.92 
Time off work and productivity costs 
Number of 
days off over 12 
months 
a
 
-1.05 0.364 -3.35, 1.23  
Mean cost (£) 
of work 
absence 
a
 
-23.25 0.845 -256.32,  209.83  
 
a  
adjusted for baseline Utility, and gender (Regression model)
 b 
Difference in mean per 
patient costs net benefits, QALYs and time off work between trial arms 
 
 
 
 
  
Page 17 of 25 Rheumatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
REFERENCES 
(1) Jinks C, Jordan K, Croft P. Disabling knee pain – another consequence of obesity: 
Results from a prospective cohort study. BMC Public 
Health 2006, 6:258 doi:10.1186/1471-2458-6-258. 
(2) Cross M, Smith E, Hoy D et al. The global burden of hip and knee osteoarthritis: 
estimates from the global burden of disease 2010 study. Ann Rheum Dis 
2014;73:1323-30. 
(3) Murray CJ, Richards MA, Newton JN, et al. UK health performance: findings from 
the Global Burden of Disease Study Lancet 2013;381:997-1020. 
(4) Royal College of General Practitioners—Birmingham Research Unit, “Annual 
prevalence report,” Tech. Rep., 2006. 
(5) Chen A, Gupte C, Akhtar K, Smith P, Cobb J. (2012) The global cost of osteoarthritis: 
How the UK compares Arthritis 2012(2012) doi:10.1155/2012/698709 
 
(6) Jordan KP, Joud A, Bergknut C et al. (2013) International comparisons of the 
consultation prevalence of musculoskeletal conditions using population-based 
healthcare data from England and Sweden Ann Rheum Dis doi:10.1136/ 
annrheumdis-2012-202634 
(7) Office for National Statistics (2014) Statistical Bulletin: Estimates of the very old 
(including centenarians) for the United Kingdom, 2002-2012 
www.ons.gov.uk/ons/dcp171778_357100.pdf  
(8) Altman RD, Hochberg MC, Moskowitz RW, Schnitzer TJ. Recommendations for the 
medical management of OA of the hip and knee: 2000 update. Arthritis  Rheum 2000, 
43: 1905-1915. 
Page 18 of 25Rheumatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
(9) Jordan KM, Arden NK, Doherty M,  et al. EULAR Recommendations 2003: an 
evidence based approach to the management of knee OA: Report of a Task Force of 
the Standing Committee for International Clinical Studies Including Therapeutic 
Trials (ESCISIT). Ann Rheum Dis 2003, 62: 1145-1155. 
(10) Zhang W, Moskowitz RW, Nuki G,  et al. OARSI recommendations for the 
management of hip and knee OA, Part I: Critical appraisal of existing treatment 
guidelines and systematic review of current research evidence. Osteoathr Cartil2007, 
15: 981-1000. 
(11) Conaghan PG, Dickson J, Grant RL. Care and management of OA in adults: 
summary of NICE guidance. BMJ 2008, 336 :502-503. 
(12) NICE (2014) Osteoarthritis: care and management in adults 
www.nice.org.uk/Guidance/CG177  
(13) Porcheret M, Jordan K, Jinks C, with the Primary Care Rheumatology Society. 
Primary care treatment of knee pain a survey in older adults. Rheumatology 2007, 46: 
1694-1700. 
(14) Steel N, Bachmann M, Maisey S,  et al. Self reported receipt of care consistent with 
32 Quality Indicators: national population survey of adults aged 50 or more in 
England. BMJ 2008, 337: a957. 
(15) Dziedzic K, Healey E, Porcheret M,  et al. (2014) Implementing the NICE 
osteoarthritis guidelines a mixed methods study and cluster randomised trial of a 
model osteoarthritis consultation in primary care. The Management of OsteoArthritis 
In ConsultationS (MOSAICS) study protocol Implement Sci 9:5 doi:10.1186/s13012-
014-0095-y   
Page 19 of 25 Rheumatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
(16) Edwards JJ, Khanna M, Jordan KP, et al (2013) Quality indicators for the primary 
care of osteoarthritis: a systematic Ann Rheum Dis 74: 490-498 
doi:10.1136/annrheumdis-2013-203913 
(17) Ware JE, Kosinski M, Keller SD (1996) A 12-item Short-Form Health Survey. 
Construction of scales and prelimnary tests of reliability and validity  Med Care 34: 
220-33  
(18)  Curtis L (2012). Unit Costs of Health and Social Care 2012 PSSRU. University of 
Kent: Canterbury .  
(19)  BMJ Group (2013). British National Formulary (BNF) 66. London: BMJ Group and 
RPS Publishing .  
(20)   Department of Health. NHS Reference Costs 2012/13. 
(21)  Rabin R, de Charro F (2001) EQ-5D: a measure of health status from the EuroQol 
Group Ann Med 33(5): 337-43  
(22)  Dolan P (1997) Modeling valuations for EuroQol health states. Med Care , 1095-
1108.  JSTOR. 
(23) Brazier JE, Roberts J (2004) The estimation of a preference- based  measure of 
health from the SF-12 Med Care 42: 851-859 
(24) Al-Janabi H, Flynn T, Coast J (2012) Development of a self-report measure of 
capability wellbeing for adults: The ICECAP-A Qual  Life Res 21: 167-176   
(25) Gomes M, Diaz-Ordaz K, Grieve R, Kenward RG (2013) Multiple imputation 
methods for handling missing data in cost-effectiveness analysis that use data from 
hierarchical studies: An application to cluster randomised trials Med Dec Making 
33(8): 1051-63 
(26) Mathews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial 
measurements in medical research. BMJ 1990;300:230-5     
Page 20 of 25Rheumatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
(27) Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial based cost 
effectiveness analysis: the importance of controlling for baseline utility. Health Econ 
14[5], 487-496. 2005.  Wiley Online Library. 
(28) Briggs AH, Gray AM (1999) Handling uncertainty when performing economic 
evaluation of health care interventions Health Technol Assess 3(2) PP 1-134 
(29)  Drummond, M.F., Sculpher, M.J., Torrance, G.W., O'brien, B.J., Stoddart, G.L. 
2005. Methods for the economic evaluation of health care programmes Oxford 
University Press, USA. 
(30) Gomes M, Ng ES, Grieve R, . (2012) Developing appropriate methods for cost-
effectiveness analysis of cluster randomised trials Med Dec Making 32(2): 350-61 
(31) Van Hout B, Al MJ, Gordon GS, Rutten FFH. Costs, effects and C/E ratios 
alongside a clinical trial. Health Econ 1994; 3:309-19 
(32)  StataCorp. LP. Stata/IC 12.1 for Windows. 2012 
(33) Carpenter JR, Goldstein H,  Kenward G. REALCOM-IMPUTE software for 
multilevel multiple imputation with mixed responses types. J Stat Soft, 2011. 
(34) Microsoft Excel for Windows, 2010, Redmont, VA, USA 
(35) Sculpher M. (2001) The role and estimation of productivity costs in economic 
evaluation; in: Drummond MF, McGuire A (eds): Economic evaluation in health care: 
merging theory with practice. Oxford:: Oxford University Press, 94-112. 
(36) Standard Occupational Classification (SOC) 2000  
http://www.ons.gov.uk/ons/guide-method/classifications/archived-standard-
classifications/standard-occupational-classification-2000/about-soc-2000/index.html 
(37) Whitehurst DG, Bryan S (2011) Another study showing that two preference based 
measures of health-related quality of life (EQ-5D and SF-6D) are not interchangeable. 
But why should we expect them to be Value  Health 14 PP 531-538 
Page 21 of 25 Rheumatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
(38) Briggs AH,  O’Brien BJ (2001) The death of cost-minimisation analysis? Health 
Econ 10(2) PP 179-184 
(39)  Brazier JE, Harper R, Munro J, Walters SJ, Snaith ML. (1999) Generic and 
condition-specific outcome measures for people with osteoarthritis of the knee. 
Rheumatology 38: 870-7 
(40)  Herdman M, Gudex C, Lloyd A et al. (2011)  Development and preliminary testing  
of the new five-level version of EQ-5D (EQ-5D-5L) Qual Life Res 20: 1727-36 
Page 22 of 25Rheumatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
 
 
297x209mm (300 x 300 DPI)  
 
 
Page 23 of 25 Rheumatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Appendix 1: The model OA consultation  
 
 
Model OA consultation with the GP 
Patients with peripheral joint pain who were aged 45 years and over had an initial consultation with 
the GP where an OA e-template was triggered as part of the consultation and GPs were asked to 
assess and make a clinical diagnosis of the problem without the routine use of x-ray. GPs were then 
asked to offer an explanation of OA (in suitable language and tailored to the patient's level of 
understanding and individual circumstances) and offer first line analgesia as appropriate (paracetamol; 
Topical NSAIDS). An OA guidebook 
(weblink:http://www.keele.ac.uk/media/keeleuniversity/ri/primarycare/pdfs/OA_Guidebook.pdf) 
written by patients and health care professionals for patients was given to the patient. It offers support 
for self-management, promotes the NICE core treatments and provides accounts of how people live 
with OA. The GP was then asked to explain the next steps: for the patient to read the OA guidebook 
and to arrange a follow-up appointment with the practice nurse. 
Model OA consultation with the Practice Nurse (nurse-led OA clinic) 
The timing of the first appointment with the practice nurse was planned for a minimum of two weeks 
after the initial GP consultation. This gave patients time to read the guidebook and try those self-
management strategies they felt were suitable. In the first consultation the practice nurse was asked to 
Patient 45 
years and 
over presents 
with 
peripheral 
joint pain 
(knee, hip, 
hand, foot)
OA 
consultation 
with the GP 
GP:
Makes, gives and 
explains the diagnosis
Addresses 
expectations and 
need for analgesia
Promotes self-
management for OA 
and provides OA 
Guidebook
OA consultation 
with the 
Practice Nurse 
Nurse supports self-
management for OA:
Information on OA and 
its treatment
Agenda and goal
setting
Advice and support on 
exercise and physical 
activity, weight loss 
and pain control
As appropriate 
referral for OA 
consultation with 
a member of the 
broader 
multidiscpilnary 
team
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refer to the guidebook as a resource to answer questions and clarify issues, ascertain the advice from 
the GP consultation, negotiate and agree appropriate goals, discuss the need for pain relief and 
opportunities for healthy eating, physical activity and exercise as appropriate.  
The timing of up to three follow-up visits with the nurse was agreed between the patient and the 
practice nurse, but was scheduled to be delivered within three months following the GP consultation. 
The follow-up practice nurse consultations were tailored to the patient’s individual needs and could 
focus on, for example, reviewing the self-management plan, demonstrating exercises (Arthritis 
Research UK Exercises for Arthritis leaflet), giving advice as to how this could be maintained longer-
term or making any necessary referrals to the broader multidisciplinary team. The practice nurse 
consultations were supported by a specifically tailored Case Report Form (available on request) and a 
nurse toolkit that included advice leaflets to give to patients (content of the toolkit available on 
request). 
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Appendix 2: Unit Costs (£) (2012/2013 prices) 
Resource Use Unit costsSource 
Primary Care visits 
a
   
GP visits per 11.7 minutes  34 
Nurse visits at practice per hour 44 
Nurse visits at home per hour 60 
Other healthcare professionals 
(attached to practice)  
Participant-specific 
Secondary care visits 
b
  
Orthopaedic surgeon 128 
Orthopaedic surgeon (follow-up) 102 
Physiotherapist 49 
Physiotherapist (follow-up) 44 
Occupational therapist 75 
Occupational therapist (follow-up) 34 
Podiatrist  74 
Podiatrist (follow-up) 41 
Other secondary care visits  Participant-specific 
Private consultants  Costed to the NHS equivalent 
Private other health care 
professionals  
Costed to the NHS equivalent 
Hospital investigations/treatments  Participant-specific 
Prescribed drugs 
c 
 Participant-specific 
Over the counter drugs  Participant-specific 
a Curtis L Unit Cost of Health and Social Care 2013 PSSRU b NHS Reference costs schedule 2012/2013, c British 
National Formulary
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